[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342139-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342139-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-microenvironment-of-epstein-barr-virus-ebv-negative-compared-to-ebv-associated-gastric-cancers-implications-for-immunotherapy","Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers - implications for immunotherapy","","Gastric carcinomas are aggressive, with only a minority of patients responding to PD-(L)1 monotherapy. Epstein-Barr virus (EBV)-associated gastric cancers show PD-L1/PD-L2 amplifications and robust CD8+ T cell infiltrates, prompting higher anti-PD-1 responsiveness. This study compares tumor immune microenvironments of EBV+ versus EBV(−) tumors using immunohistochemistry markers and gene expression profiling from CD3+ infiltrate regions, identifying pathways linked to immune suppression and therapy resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-microenvironment-of-epstein-barr-virus-ebv-negative-compared-to-ebv-associated-gastric-cancers-implications-for-immunotherapy/342139/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-microenvironment-of-epstein-barr-virus-ebv-negative-compared-to-ebv-associated-gastric-cancers-implications-for-immunotherapy/342139.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the study compare EBV+ and EBV(−) gastric cancers?","Question",{"text":63,"@type":64},"It screens over 1000 primary invasive gastric cancers to select 25 treatment-naïve specimens (11 EBV+, 14 EBV(−)), then applies quantitative immunohistochemistry and gene expression profiling focused on CD3+ T cell infiltrate areas adjacent to PD-L1+ cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What immune microenvironment differences were found between EBV+ and EBV(−) tumors?",{"text":68,"@type":64},"CD8+ T cell densities were higher in EBV+ tumors, while EBV(−) tumors showed overexpression of functionally related myeloid-associated genes, immunosuppressive cytokines/chemokines, coinhibitory molecules, and adenosine pathway components.",{"name":70,"@type":61,"acceptedAnswer":71},"Which pathway is highlighted as a potential cotarget to improve anti-PD-1 therapy?",{"text":72,"@type":64},"The study identifies upregulation of the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) tumor-promoting pathway in EBV(−) gastric cancers and nominates the COX-2 pathway as a cotarget to enhance anti-PD-1 immunotherapy effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342139,1790106993,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Open access Original research  \n Immune microenvironment of Epstein  \nBarr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy  \nTracee L McMiller  ,1,2 Sepideh Besharati,3 Mark Yarchoan,2,4 Qingfeng Zhu,4 Keziban Ünsal-Kaçmaz  ,5 Ke Xu,5 Junghwa Lee  ,1,2 Feriyl Bhaijee,3  \nLogan L Engle  ,2,6 Janis M Taube,2,6 Alan E Berger  ,1,2 Robert A Anders  ,2,3 Suzanne L Topalian  1,2  \nTo cite: McMiller TL, Besharati S, Yarchoan M, et al. Immune microenvironment of Epstein-Barr virus (EBV) -negative compared to EBVassociated gastric cancers:  \nimplications for immunotherapy. Journal for ImmunoTherapy of Cancer 2024;12:e010201 . doi:10.1136/jitc-2024-010201  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010201](jitc-2024-010201)) .  \nTLM, SB and MY contributed equally.  \nRAA and SLT contributed equally. Accepted 29 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Suzanne L Topalian; [stopali1@jhmi.edu](stopali1@jhmi.edu)  \nABSTRACT  \nBackground Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to antiprogrammed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5– 10% of GCs) often harbor PD-L1 and PD-L2 chromosomal amplifications and robust CD8+ T cell infiltrates, and respond at a high rate to anti-PD-1. The current study compares the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(−) GCs.  \nMethods Over 1000 cases of primary invasive  \nGCs were screened to identify 25 treatment-naïve specimens for study (11 EBV+, 14 EBV(−)) . Quantitative immunohistochemistry (IHC) was conducted for markers of immune cell subsets and co-regulatory molecules. Gene expression profiling (GEP) was performed on RNAs isolated from macrodissected areas of CD3+ Tcell infiltrates abutting PD-L1+ stromal/tumor cells, using multiplex quantitative reverse transcriptase PCR for a panel of 122 candidate immune-related genes.  \nResults IHC revealed that 17/25 GCs contained PD-L1+ stromal cells, with no significant difference between EBV+/ -specimens; however, only 3/25 specimens (all EBV+) contained PD-L1+ tumor cells. CD8+ Tcell densities were higher in EBV+ versus EBV(−) tumors (p=0.044). With GEP normalized to the pan-leukocyte marker PTPRC/CD45, EBV+ GCs overexpressed ITGAE (CD103, marking intraepithelial T cells and a dendritic cell subset) and the interferon-inducible genes CXCL9 and IDO1 . In contrast, EBV(−) tumors overexpressed several functionally-related gene groups associated with myeloid cells (CD163, IL1A, NOS2, RIGI), immunosuppressive cytokines/chemokines (CXCL2, CXCR4, IL10, IL32), coinhibitory molecules (HAVCR2/TIM-3 and VSIR/VISTA), and adenosine pathway components (ENTPD1/ CD39 and NT5E/CD73). Notably, compared with EBV+ GCs, EBV(−) GCs also overexpressed components of the cyclooxygenase 2 (COX-2)/ prostaglandin E2 (PGE2) pathway associated with cancerpromoting inflammation, including PTGS2/COX-2 (most highly upregulated gene, 32-fold, p=0 .005); prostaglandin receptors PTGER1 (EP1; up 21-fold, p=0 .015) and PTGER4 (EP4; up twofold, p=0 .022); and the major COX-2-inducing cytokine IL1B (up 11-fold, p=0 .019) . Consistent with  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Epstein-Barr virus (EBV)-associated gastric cancers (GCs), comprising ~5–10% of all GCs, are reported to have a much higher response rate to antiprogrammed cell death 1 (PD-1) therapy than the more common EBV(−) GC subset.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study comparing the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(−) GCs revealed a more highly immunosuppressive TiME in EBV(−) GCs, in which up","cbCaiiTS2i3chsBc","https://ap.wps.com/l/cbCaiiTS2i3chsBc","pdf",8053481,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Gastric cancer and immunotherapy context\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"How does the study compare EBV+ and EBV(−) gastric cancers?\",\"answer\":\"It screens over 1000 primary invasive gastric cancers to select 25 treatment-naïve specimens (11 EBV+, 14 EBV(−)), then applies quantitative immunohistochemistry and gene expression profiling focused on CD3+ T cell infiltrate areas adjacent to PD-L1+ cells.\"},{\"question\":\"What immune microenvironment differences were found between EBV+ and EBV(−) tumors?\",\"answer\":\"CD8+ T cell densities were higher in EBV+ tumors, while EBV(−) tumors showed overexpression of functionally related myeloid-associated genes, immunosuppressive cytokines/chemokines, coinhibitory molecules, and adenosine pathway components.\"},{\"question\":\"Which pathway is highlighted as a potential cotarget to improve anti-PD-1 therapy?\",\"answer\":\"The study identifies upregulation of the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) tumor-promoting pathway in EBV(−) gastric cancers and nominates the COX-2 pathway as a cotarget to enhance anti-PD-1 immunotherapy effects.\"}]","Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers - implications for immunotherapy | PDF",1790045456,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4903c466045cc27451c7c40b42d609d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be24dda57a6c078d23fb21d70de228a0.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b40f34c3e462004599d72732a5be4c0.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4c29ae60dc1e83134f71161d79981b1.webp",980,1306]